No profile data available.
Solid Biosciences Inc. (SLDB) is a healthcare company in the brain and nerve treatment drugs industry, based in Charlestown, United States, with about 121 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$174.33 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $736.64 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
Solid Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$736.64 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Capricor Therapeutics, Inc. (CAPR), Alto Neuroscience, Inc. (ANRO), Annexon, Inc. (ANNX), Design Therapeutics, Inc. (DSGN).